safety was observed across 88 healthy volunteers. Phase 2 plans to test whether ENV-308 can help people maintain their weight after stopping GLP-1s.
- ENV-308 is the first drug in human trials designed to mimic Lac-Phe, a pseudo dipeptide hormone released by the body in response to high-intensity exercise.
- In its first clinical trial, ENV-308 was extremely well tolerated across 88 healthy volunteers, including for gastrointestinal safety – the most common side effect that leads to people stopping GLP-1 medicines.
- The trial showed ENV-308 reduced circulating leptin, an exploratory signal that the drug reaches biology relevant to metabolic disease.
- In animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped.
- Enveda plans a series of future trials, including in people who discontinued or are planning to discontinue GLP-1 therapy, and is evaluating other conditions where the effects of exercise are known to be beneficial.